$212.81
1.71% day before yesterday
Nasdaq, Dec 24, 08:25 pm CET
ISIN
US04351P1012
Symbol
ASND

Ascendis Pharma A/S Sponsored ADR Stock price

$212.81
+3.78 1.81% 1M
+33.71 18.82% 6M
+75.14 54.58% YTD
+74.02 53.33% 1Y
+93.72 78.70% 3Y
+41.87 24.49% 5Y
+194.94 1,090.88% 10Y
+193.98 1,030.16% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+3.58 1.71%
ISIN
US04351P1012
Symbol
ASND
Industry

Key metrics

Basic
Market capitalization
$13.0b
Enterprise Value
$13.3b
Net debt
$323.5m
Cash
$635.1m
Shares outstanding
61.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
17.1 | 15.3
EV/Sales
17.5 | 15.6
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-9.0%
Return on Equity
357.7%
ROCE
-86.6%
ROIC
-136.4%
Debt/Equity
-4.7
Financials (TTM | estimate)
Revenue
$761.7m | $852.1m
EBITDA
$-153.6m | $-104.8m
EBIT
$-171.7m | $-147.2m
Net Income
$-274.4m | $-236.0m
Free Cash Flow
$-132.1m
Growth (TTM | estimate)
Revenue
97.5% | 98.9%
EBITDA
57.1% | 66.3%
EBIT
53.8% | 55.2%
Net Income
45.4% | 47.0%
Free Cash Flow
57.3%
Margin (TTM | estimate)
Gross
86.8%
EBITDA
-20.2% | -12.3%
EBIT
-22.6%
Net
-36.0% | -27.7%
Free Cash Flow
-17.4%
More
EPS
$-4.5
FCF per Share
$-2.1
Short interest
6.7%
Employees
1k
Rev per Employee
$420.0k
Show more

Is Ascendis Pharma A/S Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Ascendis Pharma A/S Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

23 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:

22x Buy
96%
1x Hold
4%

Analyst Opinions

23 Analysts have issued a Ascendis Pharma A/S Sponsored ADR forecast:

Buy
96%
Hold
4%

Financial data from Ascendis Pharma A/S Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
762 762
97% 97%
100%
- Direct Costs 101 101
72% 72%
13%
661 661
102% 102%
87%
- Selling and Administrative Expenses 461 461
45% 45%
61%
- Research and Development Expense 345 345
6% 6%
45%
-154 -154
57% 57%
-20%
- Depreciation and Amortization 18 18
28% 28%
2%
EBIT (Operating Income) EBIT -172 -172
54% 54%
-23%
Net Profit -274 -274
45% 45%
-36%

In millions USD.

Don't miss a Thing! We will send you all news about Ascendis Pharma A/S Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ascendis Pharma A/S Sponsored ADR Stock News

Positive
Seeking Alpha
11 days ago
Ascendis Pharma is rated a cautious buy amid acquisition speculation, robust revenue growth, and a pivotal FDA decision on TransCon CNP. Yorvipath and Skytrofa drove Q3 revenues to €213.6 million, nearly quadrupling year-over-year, with operating profitability achieved for the quarter. TransCon CNP, targeting achondroplasia, faces a critical FDA PDUFA date on February 28th, with multi-billion-e...
Positive
Market Watch
15 days ago
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull market.
Positive
Seeking Alpha
15 days ago
The Touchstone Mid Cap Growth Fund outperformed its benchmark, the Russell Midcap® Growth Index, for the quarter ended September 30, 2025. From a factor perspective, the Fund's overweight exposure to size was a relative tailwind to performance, offsetting a headwind from being underweight volatility. Consumer Discretionary was the largest source of relative gains.
More Ascendis Pharma A/S Sponsored ADR News

Company Profile

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes on its TransCon technologies to create prodrugs that provide for the predictable and sustained release of an unmodified parent drug. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Head office Denmark
CEO Jan Mikkelsen
Employees 1,017
Founded 2006
Website ascendispharma.dk

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today